NEWS WRAP: Ribo Life enters Hong Kong biotech fast lane after strong debut
Shares of China’s leading developer of small interfering RNA therapeutics, or siRNA, jumped 42% in their Friday debut, and continued to climb on Monday By Doug Young Hong Kong…
BRIEF: Leading RNA drug developer Ribo passes Hong Kong listing hearing, kicking off IPO
Leading RNA drug developer Suzhou Ribo Life Science Co. Ltd. passed its hearing for a listing on the Hong Kong Stock Exchange, marking the official launch of its IPO, according…
